Cleave Therapeutics Announces Commencement of a Phase 1 Clinical Study of CB-5339\, A Valosin-Containing Protein (VCP)/p97 Inhibitor\, in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)